Roche has unveiled a new upgrade to its pharma research and early development center (pRED) in Basel, Switzerland, aimed at boosting its drug discovery output and internal collaboration.
The company has invested CHF1.2bn ($1.4bn) in the creation of the new center, which introduces new time-saving technologies to help speed drug discovery, and brings together around 1,800 researchers in two high-rise laboratory buildings
Key Takeaways
-
Roche’s newest hit, ophthalmology treatment Vabysmo, was discovered in Basel, but the group has had less recent success in oncology
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
